AstraZeneca launches $1.5 billion annual cost-saving plan to offset late-stage trial setbacks
read at Endpoints ↗Negative
AstraZeneca announced a new cost‑saving initiative targeting $1.5 billion of annual expenses.
The move follows a series of late‑stage clinical trial failures that have pressured the company's pipeline.
The savings drive is part of a broader effort to reach its $80 billion revenue target for 2030.
The strategy mirrors a similar program recently undertaken by rival GSK.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “AstraZeneca follows GSK with $1.5B annual savings push”
read at Endpoints ↗76 words · retrieved 1h ago
comments(0)
5-min edit window · permanent after that